RELAY: Ramucirumab Shows Benefit in Metastatic Lung Cancer

The RELAY trial compared the combination of ramucirumab plus erlotinib vs erlotinib alone in patients with metastatic non –small-cell lung cancer.

Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news